Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non Operating Income (2022 - 2025)

Taysha Gene Therapies' Other Non Operating Income history spans 4 years, with the latest figure at -$37000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income rose 54.32% year-over-year to -$37000.0; the TTM value through Sep 2025 reached -$669000.0, down 101.91%, while the annual FY2024 figure was -$110000.0, 100.32% down from the prior year.
  • Other Non Operating Income for Q3 2025 was -$37000.0 at Taysha Gene Therapies, up from -$122000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $34.7 million in Q4 2023 and bottomed at -$408000.0 in Q4 2024.
  • The 4-year median for Other Non Operating Income is -$8000.0 (2023), against an average of $2.6 million.
  • The largest YoY upside for Other Non Operating Income was 579133.33% in 2023 against a maximum downside of 1800.0% in 2023.
  • A 4-year view of Other Non Operating Income shows it stood at -$6000.0 in 2022, then skyrocketed by 579133.33% to $34.7 million in 2023, then crashed by 101.17% to -$408000.0 in 2024, then surged by 90.93% to -$37000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Other Non Operating Income are -$37000.0 (Q3 2025), -$122000.0 (Q2 2025), and -$102000.0 (Q1 2025).